McKesson Health Solutions President Emad Rizk, MD to Speak at Personalized Medicine Conference

Personalized medicine uses genetic information to pinpoint the right diagnosis and treatment for each individual, and the right use of diagnostic testing can have a significant impact on reducing the total cost of care while improving outcomes. In light of reform and the changing healthcare landscape, it is critical for industry leaders to exchange views about the implications of personalized medicine. This year's two-day conference will highlight the current clinical impact of personalized medicine as its use increases and how recent experience can guide and inform the policies, plans and actions of key stakeholders.

“McKesson is proud to participate in this important event as part of our strong commitment to advancing personalized medicine,” said Rizk. “Our comprehensive Advanced Diagnostics Management solution with leading evidence-based molecular diagnostics criteria creates a personalized medicine decision-making framework and fosters mutual trust among patients, payors, providers and labs. The conference provides a forum for the exchange of ideas that can further the application of this science in clinical settings in a timely and effective way.”

Rizk will be one of several influential healthcare executives on a panel discussing information technology solutions for personalized medicine. A world renowned healthcare industry expert, he serves on multiple not-for-profit and academic boards, and has an extensive roster of published works and speaking engagements. This year, he was named one of the 50 Most Powerful Physician Executives by Modern Physician for the third time in a row, and one of the Top 100 Most Powerful People in Healthcare by Modern Healthcare for the second consecutive year.

With a new molecular test being introduced every 3-5 days and the market for these tests growing at more than 20% annually, issues around test use, coding, reimbursements and authorization are compounding. McKesson’s Advanced Diagnostics Management ™ solution helps health plans and clinical labs address the challenges of ensuring appropriate utilization and reimbursement for advanced diagnostic testing. For health plans, the suite combines real-time decision support technology with evidence-based content and analytics services that drive effective use of molecular diagnostics and help manage the total cost of care. The suite also enables clinical labs to understand coverage for tests before they are performed, manage their reference lab networks and meet increasingly stringent payor requirements. By making information transparent to key stakeholders, the Advanced Diagnostics Management solution improves delivery of the right care while reducing administrative costs.